Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Sponsor
Zhengzhou University
Study ID
NCT03376958
Phase
PHASE4
Status
Completed

Conditions

  • Diffuse Large B Cell Lymphoma
  • Relapsed and Refractory

Eligibility Criteria

Sex
ALL
Age
14 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.

Study Details

The purpose of this study is to evaluate the efficacy and safety of Apatinib for patients with Relapsed Refractory Diffuse Large B Cell Lymphoma.

Key Dates

Start date
Jan 1, 2017
Status verified
Jul 2019
Primary completion
Feb 1, 2019
Completion
Apr 30, 2019

Study Design

Enrollment
32 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.

Primary Outcome Measure

Overall Response Rate [ Time Frame: up to end of follow-up-phase ]

Related Studies